Multiple Myeloma Management

Multiple Myeloma Management icon

ASO Keyword Dashboard

Tracking 17 keywords for Multiple Myeloma Management in Apple App Store

Developer: Med Learning Group Category: medical

Multiple Myeloma Management tracks 17 keywords (1 keyword ranks; 16 need traction). Key metrics: 0% top-10 coverage, opportunity 69.4, difficulty 35.1, best rank 68.

Tracked keywords

17

1  ranked •  16  not ranking yet

Top 10 coverage

0%

Best rank 68 • Latest leader —

Avg opportunity

69.4

Top keyword: clinical

Avg difficulty

35.1

Lower scores indicate easier wins

Opportunity leaders

  • clinical

    Opportunity: 72.0 • Difficulty: 37.6 • Rank —

    Competitors: 14

    62.4
  • approved

    Opportunity: 72.0 • Difficulty: 37.1 • Rank —

    Competitors: 39

    61.0
  • novel

    Opportunity: 71.0 • Difficulty: 32.9 • Rank —

    Competitors: 11

    54.6
  • agents

    Opportunity: 71.0 • Difficulty: 34.5 • Rank —

    Competitors: 9

    57.3
  • trials

    Opportunity: 70.0 • Difficulty: 29.9 • Rank —

    Competitors: 10

    49.6

Unranked opportunities

  • clinical

    Opportunity: 72.0 • Difficulty: 37.6 • Competitors: 14

  • approved

    Opportunity: 72.0 • Difficulty: 37.1 • Competitors: 39

  • novel

    Opportunity: 71.0 • Difficulty: 32.9 • Competitors: 11

  • agents

    Opportunity: 71.0 • Difficulty: 34.5 • Competitors: 9

  • trials

    Opportunity: 70.0 • Difficulty: 29.9 • Competitors: 10

High competition keywords

  • data

    Total apps: 83,822 • Major competitors: 465

    Latest rank: — • Difficulty: 49.8

  • multiple

    Total apps: 66,164 • Major competitors: 556

    Latest rank: 88 • Difficulty: 48.8

  • well

    Total apps: 44,343 • Major competitors: 255

    Latest rank: — • Difficulty: 46.9

  • important

    Total apps: 43,216 • Major competitors: 239

    Latest rank: — • Difficulty: 46.9

  • management

    Total apps: 41,446 • Major competitors: 141

    Latest rank: — • Difficulty: 46.5

All tracked keywords

Includes opportunity, difficulty, rankings and competitor benchmarks

Major Competitors
multiple681004981

66,164 competing apps

Median installs: 50

Avg rating: 4.1

8868

556

major competitor apps

management691004777

41,446 competing apps

Median installs: 25

Avg rating: 4.1

141

major competitor apps

important691004778

43,216 competing apps

Median installs: 25

Avg rating: 4.1

239

major competitor apps

trials701003050

915 competing apps

Median installs: 125

Avg rating: 4.2

10

major competitor apps

data671005083

83,822 competing apps

Median installs: 25

Avg rating: 4.1

465

major competitor apps

well691004778

44,343 competing apps

Median installs: 50

Avg rating: 4.1

255

major competitor apps

considering701003050

1,007 competing apps

Median installs: 50

Avg rating: 4.1

5

major competitor apps

clinical721003862

5,283 competing apps

Median installs: 25

Avg rating: 4.2

14

major competitor apps

preliminary681002440

258 competing apps

Median installs: 25

Avg rating: 4.1

1

major competitor apps

mechanism701003050

954 competing apps

Median installs: 25

Avg rating: 4.0

2

major competitor apps

approved721003761

4,383 competing apps

Median installs: 50

Avg rating: 4.1

39

major competitor apps

novel711003355

1,808 competing apps

Median installs: 125

Avg rating: 4.2

11

major competitor apps

agents711003457

2,618 competing apps

Median installs: 25

Avg rating: 4.2

9

major competitor apps

recognizing701003050

922 competing apps

Median installs: 25

Avg rating: 4.1

1

major competitor apps

implementing691002847

654 competing apps

Median installs: 25

Avg rating: 4.1

0

major competitor apps

clinical trials671002236

139 competing apps

Median installs: 50

Avg rating: 4.2

0

major competitor apps

efficacy671002237

162 competing apps

Median installs: 25

Avg rating: 4.2

0

major competitor apps

17 keywords
1 of 1

App Description

Bispecific antibodies are a novel mechanism in the management in the relapsed/refractory multiple myeloma. Recognizing the mechanism of these agents as well as preliminary efficacy data is important in considering clinical trials and implementing approved bispecific antibodies in the management of multiple myeloma.